The cost-effectiveness of palivizumab in the prevention of respiratory syncytial virus bronchiolitis: A systematic review

Current Respiratory Medicine Reviews

Volumn 7, Issue 3, 2011, Pages 203-212

  Blanken, Maarten ^a   Bont, Louis ^a   Rovers, Maroeska ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cost effectiveness; Palivizumab; Prophylaxis; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHRONIC LUNG DISEASE; CONGENITAL HEART DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; GESTATIONAL AGE; HOSPITAL COST; HUMAN; PREMATURITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SYSTEMATIC REVIEW; VIRAL BRONCHIOLITIS;

EID: 79956268960     PISSN: 1573398X     EISSN: 18756387     Source Type: Journal    
DOI: 10.2174/157339811795589531     Document Type: Article

References (47)

1. Reeve CA, Whitehall JS, Buettner PG, Norton R, Reeve DM, Francis F. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J Paediatr Child Health 2006; 42(5): 253-8.
2. Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. J Med Econ 2009; 12(4): 291-300.
3. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360(6): 588-98.
4. Smyth RL, Openshaw PJ. Bronchiolitis. Lancet 2006; 368(9532): 312-22.
5. Ermers MJ, Rovers MM, van Woensel JB, Kimpen JL, Bont LJ. The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial. BMJ 2009; 338: b897.
6. Bont L, Kimpen JL. Immunological mechanisms of severe respiratory syncytial virus bronchiolitis. Intensive Care Med 2002; 28(5): 616-21.
7. Tissing WJE, Van Steensel-Moll HA, Offringa M. Risk factors for mechanical ventilation in respiratory syncytial virus infection. Eur J Pediatr 1993; 152: 125-7.
8. Bont L, Aalderen vWMC, Kimpen JLL. Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis. Paediatr Respir Rev 2000; 1(3): 221-7.
9. Bont L, Steijn M, van Aalderen WM, Kimpen JL. Impact of wheezing after respiratory syncytial virus infection on health- related quality of life. Pediatr Infect Dis J 2004; 23(5): 414-7.
10. Simon A, Ammann RA, Wilkesmann A, et al. Respiratory syncytial virus infection in 406 hospitalized premature infants: results from a prospective German multicentre database. Eur J Pediatr 2007; 166(12): 1273-83.
11. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003; 143(5 Suppl): S150-S156.
12. Prais D, Schonfeld T, Amir J. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use. Pediatrics 2003; 112(3 Pt 1): 548-52.
13. Stensballe LG, Devasundaram JK, Simoes EA. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J 2003; 22(2 Suppl): S21-S32.
14. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998; 102(3 Pt 1): 531-7.
15. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143(4): 532-40.
16. GIP database, Dutch database of medical resources and medicines. GIP database, Drug Information System of the Health Care Insurance Board 2010 [cited 2010 Feb 2]; Available from: URL: http://www.gipdatabank.nl/
17. Isaacs D. Palivizumab. An example of indication creep. BMJ 2009; 339: b2724.
18. Meissner HC, Bocchini JA, Jr., Brady MT, Hall CB, Kimberlin DW, Pickering LK. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus. Pediatrics 2009; 124(6): 1676-9.
19. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for the Economic Evaluation of Health Care Programmes. 3 ed. Oxford University Press; 2005.
20. FXHistory; Historical Exchange rates. OANDA 2010 [cited 2010 Feb 2]; Available from: URL: http://www.oanda.com/currency/ historical-rates
21. Eurostat. Eurostat 2010 [cited 2010 Feb 2]; Available from: URL: http://epp.eurostat.ec.europa.eu/portal/page/portal/eurostat/home/
22. United States Department of Labor. Bureau of Labor Statistics 2010 [cited 2010 Feb 2];Available from: URL: http://www.bls.gov/CPI/
23. Australian Bureau of Statistics. Australian Bureau of Statistics 2010 [cited 2010 Feb 2];Available from: URL: http://www.abs.gov.au/
24. Reserve Bank of New Zealand. Reserve Bank of New Zealand 2010 [cited 2010 Feb 2];Available from: URL: http://www.rbnz.govt.nz/statistics/
25. Statistics Canada. Statistics Canada 2010 [cited 2010 Feb 2];Available from: URL: http://www.statcan.gc.ca/
26. Institutio Nacional de Estadistica y Censos. Institutio Nacional de Estadistica y Censos 2010 [cited 2010 Feb 2];Available from: URL: http://www.indec.mecon.ar/
27. Laufer F. Thresholds in cost-effectiveness analysis--more of the story. Value Health 2005; 8(1): 86-7.
28. Chirico G, Ravasio R, Sbarigia U. Cost-utility analysis of palivizumab in Italy: Results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Ital J Pediat 2009; 35(1): 4.
29. Elhassan NO, Sorbero MES, Hall CB, Stevens TP, Dick AW. Cost- effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006; 160(10): 1070-6.
30. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost- effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999; 104(3 I): 419-27.
31. Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ 2010; 11(1): 105-15.
32. Resch B, Gusenleitner W, Nuijten MJC, Lebmeier M, Wittenberg W. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin Ther 2008; 30(4): 749-60.
33. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: Hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000; 154(1): 55-61.
34. Vogel AM, McKinlay MJ, Ashton T, et al. Cost-effectiveness of palivizumab in New Zealand. J Paediatr Child Health 2002; 38(4): 352-7.
35. Nuijten MJC, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: A UK analysis. PharmacoEconomics 2007; 25(1): 55-71.
36. Lanctot KL, Masoud ST, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: A Canadian-based analysis. Curr Med Res Opin 2008; 24(11): 3223-37.
37. Lofland JH, Touch SM, O'Connor JP, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: A cost- effectiveness analysis. Clin Ther 2000; 22(11): 1357-69.
38. Rodriguez SP, Farina D, Bauer G. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: A cost- effectiveness analysis. Pediatr Infect Dis J 2008; 27(7): 660-1.
39. Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003; 162(4): 237-44.
40. Meberg A, Bruu AL. Respiratory syncytial virus infections in congenital heart defects - Hospitalizations and costs. Acta Paediatr Int J Paediatr 2006; 95(4): 404-6.
41. Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab in children with congenital heart disease in Germany. J Med Econ 2009; 12(4): 301-8.
42. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with conge ital heart disease. Pediatrics 2004; 114(6): 1606-11.
43. Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: A systematic review and economic evaluation. Health Technol Assess 2008; 12(36): 1-86.
44. Prescott WA, Jr., Doloresco F, Brown J, Paladino JA. Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review. Pharmacoeconomics 2010; 28(4): 279-93.
45. Embleton ND, Harkensee C, Mckean MC. Palivizumab for preterm infants. Is it worth it? Arch Dis Child Fetal Neonatal Ed 2005; 90(4): F286-9.
46. Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child 2009; 94(2): 99-103.
47. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003; 143(5 Suppl): S150-6.